The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over competitors’ more frequent regimens.

Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.

Data from the largest US Lyme disease registry suggests that 90% of PLD patients are excluded from clinical trials.

The US Food and Drug Administration has issued guidance urging sponsors and trial sites to consider the necessity of the invasive procedure.

CytoMed Therapeutics has signed a business and research collaboration agreement with SunAct Cancer Institute for a clinical trial in India.

VYNE Therapeutics has completed enrolment in the randomised Phase IIb clinical trial of VYN201 gel for treating non-segmental vitiligo.

I-Mab said the measure ensures cash reserves to keep the company operational until 2027. Image credit: Brian A Jackson / Shutterstock Cancer immunotherapy biotech I-Mab, has paused the development of ...

After disappointing Phase IIb results for avicursen in December, Percheron will adopt a three-pronged business strategy.

Oculis has reported that the Phase II ACUITY trial of OCS-05, in treating individuals with acute optic neuritis, met the primary endpoint ...

The Australian Government has announced the ‘2024 Clinical Trial Enabling Infrastructure’ grant opportunity, offering A$35.7m for research.

Chime Biologics and Mabgeek have completed the Process Performance Qualification (PPQ) for the humanised anti-IL-4Rα monoclonal antibody, MG-K10, advancing it into Phase III clinical trials for a ...

Following a recent trial, doctors at the Christie Hospital are optimistic about the study of HMBD-001 in the treatment of bladder cancer.